A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Trelstar Warnings, Precautions, Pregnancy, Nursing, Abuse - Triptorelin pamoate
Trelstar Warnings, Precautions, Pregnancy, Nursing, Abuse - Triptorelin pamoate
WARNINGS
Initially, triptorelin, like other LHRH agonists, causes a
transient increase in serum testosterone levels. As a result, isolated cases
of worsening of signs and symptoms of prostate cancer during the first weeks
of treatment have been reported with LHRH agonists. Patients may experience
worsening of symptoms or onset of new symptoms, including bone pain, neuropathy,
hematuria, or urethral or bladder outlet obstruction. Cases of spinal cord compression,
which may contribute to paralysis with or without fatal complications, have
been reported with LHRH agonists.
If spinal cord compression or renal impairment develops, standard
treatment of these complications should be instituted, and in extreme cases
an immediate orchiectomy considered.
TRELSTARTM DEPOT should not be administered
to individuals who are hypersensitive to triptorelin, other LHRH agonists, or
LHRH. In the event of a hypersensitivity reaction, therapy with TRELSTARTM
DEPOT should be discontinued immediately and the appropriate supportive
and symptomatic care should be administered.
PRECAUTIONS
General: Patients with metastatic vertebral lesions
and/or with upper or lower urinary tract obstruction should be closely observed
during the first few weeks of therapy (see WARNINGS
).
Hypersensitivity and anaphylactic reactions have been reported with triptorelin
as with other LHRH agonists (see CONTRAINDICATIONS
and WARNINGS
).
Laboratory Tests: Response to TRELSTARTM DEPOT
should be monitored by measuring serum levels of testosterone and prostate-specific
antigen.
top
